Challenges associated with the evaluation of veterinary product bioequivalence: An AAVPT perspective

Journal of Veterinary Pharmacology and Therapeutics

Volumn 25, Issue 3, 2002, Pages 201-220

  Martinez, M ^a   Langston, C ^b   Martin, T ^c   Conner, D ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Department of Basic Sciences   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOEQUIVALENCE; DRUG DOSAGE FORM; DRUG INDUSTRY; MEAL; PRIORITY JOURNAL; TECHNOLOGY; UNITED STATES; VETERINARY MEDICINE;

ANIMALS; DRUG APPROVAL; DRUG INDUSTRY; EVALUATION STUDIES; LEGISLATION, DRUG; PRACTICE GUIDELINES; THERAPEUTIC EQUIVALENCY; UNITED STATES; VETERINARY DRUGS;

ANIMALIA;

EID: 0036304506     PISSN: 01407783     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2885.2002.00407.x     Document Type: Article

References (61)

1. The effect of mannitol on the oral bioavailability of cimetidine
2. Polysorbate 80 and E-Ferol toxicity
3. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability
4. Gastric emptying of tablets and granules in humans, dogs, pigs and stomach-emptying-controlled rabbits
5. Testing for the equality of area under the curves when using destructive measurement techniques
6. Statistical comparison of dissolution curves
7. Bioequivalence: Performance of several measures of extent of absorption
8. Coverage and precision of confidence intervals for area under the curve using parametric and non-parametric methods in a toxicokinetic experimental design
9. Gastrointestinal pharmacology
10. Maximum entropy and its application to the calculation of drug absorption rates
11. The role of metabolites in bioequivalency assessment. I. Linear pharmacokinetics without first-pass effect
12. Propofol hydroxylation by dog liver microsomes: Assay development and dog breed differences
13. Sex differences in the disposition of albendazole metabolites in sheep
14. Pharmacokinetics of phenolsulfonphthalein in sheep
15. Planning and monitoring of equivalence studies
16. Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence
17. Polysorbate toxicity in neonatal rats and mice
18. Interim analyses in randomized clinical trials: Ramifications and guidelines for practitioners
19. Chronic local tissue reactions, long-term immunogenicity and immunologic priming of mice and guinea pigs to tetanus toxoid encapsulated in biodegradable polymer microspheres composed of polylactide co-glycolide polymers
20. Drug metabolite kinetics
21. Application of moment analysis in assessing rates of absorption for bioequivalency studies
22. A method of statistical comparison of bioavailability when only one concentration-time point per individual is available
23. In vitro and in vivo evaluation in dogs and pigs of a hydrophilic matrix containing propylthiouracil
24. Application of the NONMEM method to evaluation of the bioavailability of drug products
25. Penetration and enzymatic barriers to peptide and protein absorption
26. Mucosal penetration enhancers for facilitation of peptide and protein drug absorption
27. Bioequivalence of ivermectin formulations in pigs and cattle
28. Nonlinear kinetics of alendronate: Plasma protein binding and bone uptake
29. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs
30. A comparative computer simulation study of three different sparse-sampling methods for estimation of steady state area under the concentration-time curve (AUC) and maximum concentration (Cmax) in toxicokinetics
31. Feasibility of interspecies extrapolation in determining the bioequivalence of animal products intended for intramuscular administration
32. Review of the 1993 veterinary drug bioequivalence workshop
33. Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: Correlation with its hypotensive action in dogs
34. Volume of distribution for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations
35. The application of partial areas in assessment of rate and extent of absorption in bioequivalence studies of conventional release products: Experimental evidence
36. Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis
37. Influence of adjunctive ticlopidine on the treatment of experimental Staphylococcus aureus endocarditis
38. The bioavailability of diazepam from uncoated tablets in humans - Part II: Effect of gastric fluid acidity
39. Pharmacokinetics of diflubenzuron in two types of chickens
40. Bioequivalence: Individual and population compartmental modeling compared to the noncompartmental approach
41. Bioavailability of total and unbound disopyramide: Implications for clinical use of the immediate release and controlled-release dosage form
42. Group sequential methods in the design and analysis of clinical trials
43. Interim analyses for randomized clinical trials: The group sequential approach
44. Measurement of zeranol in plasma from three blood vessels in steers implanted with zeranol
45. Doxycycline binding to plasma albumin of several species
46. Allometric analysis of doxycycline pharmacokinetic parameters
47. Plasma protein binding displacement interactions - Why are they still regarded as clinically important?
48. The sensitization potential of some perfume ingredients tested using a modified Draize procedure
49. Plasma protein binding and pharmacological response
50. Controversies in bioequivalence studies
51. Limited-sampling strategy models for estimating the area under the plasma concentration-time curve for amlodipine
52. Teratogenic effects of polyethylene glycol 200 in the mouse but not in the rat
53. Center of gravity of drug level curves: A model-independent parameter useful in bioavailability studies
54. Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide
55. The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy
56. Dose-dependent plasma clearance of MK-826, a carbapenem antibiotic, arising from concentration-dependent plasma protein binding in rats and monkeys
57. Dose-dependent pharmacokinetics and metabolism of valproic acid in newborn lambs and adult sheep
58. Reversal of multidrug resistance by surfactants
59. Can bioavailability of low-variance drugs be estimated with an unpaired, sparse sampling design?
60. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability